To explore the translational potential of Chek2 modulation in the context of anti-PD-1 immunotherapy in gliomas, the blood-brain barrier permeable Chek1/2 inhibitor Prexasertib (LY2606368) which is being evaluated in clinical trials32–35, was tested in vivo. Here, CHEK2 is linked to glioma.